Press release
Vulvovaginal Candidiasis (VVC) Market to Reach USD 1.76 Billion by 2030
Vulvovaginal Candidiasis
VVC-commonly known as a yeast infection-is primarily caused by Candida albicans, but non-albicans Candida species are increasingly reported, driving demand for more effective and targeted therapeutic solutions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73638
Key Takeaways
• Market Size 2023: USD 1.15 billion
• Market Size 2030: USD 1.76 billion
• CAGR (2024-2030): 5.8%
• Largest Segment: Over-the-counter (OTC) antifungal products
• Fastest-Growing Segment: Diagnostics & treatments for recurrent VVC (RVVC)
Market Story
Vulvovaginal candidiasis is one of the most common fungal infections affecting women globally. Over 75% of women experience at least one episode, and recurrent VVC affects nearly 5-9%. Growth of the market is fueled by:
• Rising prevalence due to antibiotic use, hormonal changes, contraceptive use, and diabetes
• Increased incidence of non-albicans Candida strains
• Higher recurrence rates requiring long-term therapy
• Expansion of OTC antifungals for self-managed care
• New clinical guidelines supporting evidence-based treatment
• Growing adoption of molecular diagnostics for accurate species identification
Demand for convenient, fast-acting, and recurrence-preventing treatments continues to rise across pharmacies, clinics, and telehealth platforms.
Market Segments
By Treatment Type
• OTC Antifungal Products - Largest Segment
- Clotrimazole
- Miconazole
- Tioconazole
• Prescription Antifungals
- Fluconazole (standard of care)
- Itraconazole
- Terconazole
• Long-Term Maintenance Therapies for RVVC
• Novel Drugs Under Development
- Oteseconazole (next-generation azole)
- Ibrexafungerp (first-in-class triterpenoid antifungal)
• Probiotics & Microbiome-Based Therapies
• Supportive Care Products
Next-generation antifungals are reshaping treatment for recurrent and resistant infections.
By Diagnosis Method
• Clinical Examination (Primary Diagnostic Step)
• Microscopy & Culture Tests
• PCR-Based Molecular Tests (Fastest Growing)
- Species-level identification
- Drug-resistance markers
• Point-of-Care Rapid Tests
• Self-Testing Kits (Emerging)
Molecular testing is increasingly recommended for accurate RVVC diagnosis.
By Disease Type
• Acute VVC (Largest Share)
• Recurrent VVC (RVVC)
• Complicated & Non-Albicans VVC
RVVC is a key commercial focus due to high relapse rates and unmet therapeutic needs.
By End User
• Retail Pharmacies (Largest Distribution Channel)
• Hospital & Specialty Clinics
• Diagnostic Laboratories
• Online Pharmacies & Telehealth Platforms (Fastest Growing)
• Women's Health Centers
Online and telemedicine-based diagnosis and prescriptions are expanding rapidly.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73638/vulvovaginal-candidiasis-vvc-market
Recent Industry Developments
• 2024 - Scynexis expanded access to ibrexafungerp for resistant & recurrent VVC cases.
• 2023 - Mycovia Pharmaceuticals advanced oteseconazole for RVVC after positive global studies.
• 2023 - Bayer & J&J strengthened OTC antifungal portfolios in key markets.
• 2023 - BD launched enhanced PCR-based panels for women's health diagnostics.
• 2023 - Telehealth platforms increased VVC consultation services globally.
Expert Quote
"Growing awareness, better diagnostics, and the rise of next-generation antifungals are transforming how recurrent and resistant VVC is managed-improving outcomes and convenience for millions of women worldwide."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy
Key Market Drivers
1. Rising Global VVC Prevalence
Hormonal imbalance, diabetes, contraceptive use, and widespread antibiotic consumption continue to elevate infection rates.
2. Growth in OTC Antifungal Use
Self-care and rapid-relief products dominate consumer preferences.
3. Emergence of Drug-Resistant Strains
Non-albicans Candida and antifungal-resistant species require advanced diagnostics and novel therapies.
4. Increase in Recurrent VVC Cases
RVVC requires long-term, targeted treatment approaches driving new product development.
5. Expansion of Digital Health & Telemedicine
Women increasingly access diagnosis, prescriptions, and OTC products through digital platforms.
Forecast Outlook (2024-2030)
Future market growth will be driven by:
• Adoption of personalized microbiome-based therapies
• Wider use of PCR diagnostics for species identification
• Development of antifungal agents with improved resistance profiles
• Growth of online pharmacies & virtual OB-GYN consultations
• Expanded education campaigns focused on women's health
By 2030, VVC management will be more precise, personalized, and digitally integrated.
Regional Insights
North America
Largest market due to high awareness, improved diagnostics, and strong OTC antifungal sales.
Europe
Growth driven by expanded women's health programs and digital pharmacy adoption.
Asia-Pacific (Fastest Growing Region)
High population density, rising infection rates, and OTC antifungal availability fuel demand.
Latin America & Middle East
Increasing access to women's health services supports gradual market expansion.
Conclusion
The Vulvovaginal Candidiasis Market is growing steadily as improved diagnostics, evolving antifungal therapies, and expanding telehealth services reshape clinical management. With rising recurrence rates and emerging resistant species, the demand for advanced, patient-centric treatment options will continue to increase through 2030.
This report is also available in the following languages : Japanese (外陰膣カンジダ症(VVC)市場), Korean (외음질칸디다증(VVC) 시장), Chinese (外阴阴道念珠菌病 (VVC) 市场), French (Marché de la candidose vulvo-vaginale (VVC)), German (Markt für vulvovaginale Candidiasis (VVC).), and Italian (Mercato della candidosi vulvovaginale (VVC).), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73638
Related Reports
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Market
https://exactitudeconsultancy.com/reports/73655/human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-clinical-market
High-Grade Glioma Clinical Market
https://exactitudeconsultancy.com/reports/73656/high-grade-glioma-clinical-market
Lennox-Gastaut Syndrome Clinical Market
https://exactitudeconsultancy.com/reports/73657/lennox-gastaut-syndrome-clinical-market
Frozen Shoulder Syndrome Clinical Market
https://exactitudeconsultancy.com/reports/73658/frozen-shoulder-syndrome-clinical-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vulvovaginal Candidiasis (VVC) Market to Reach USD 1.76 Billion by 2030 here
News-ID: 4293220 • Views: …
More Releases from Exactitude Consultancy
Emotion Detection & Recognition Market Surges as AI, Biometrics, and Behavioral …
The Emotion Detection and Recognition (EDR) Market is expanding rapidly as AI-powered systems become capable of interpreting human emotions through facial expressions, voice patterns, biometric signals, and behavioral cues. With adoption accelerating across customer experience, automotive safety, healthcare, retail, and educational technology, EDR is emerging as a foundational layer of next-generation intelligent systems.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/74632
Emotion Detection and Recognition Market Overview
The global Emotion Detection and…
Hyperglycemia Clinical Market to Reach USD 24.9 Billion by 2030
The Global Hyperglycemia Clinical Market is expanding rapidly as healthcare systems respond to rising diabetes prevalence, acute hyperglycemia episodes, and increased demand for real-time glucose monitoring and insulin management. According to Exactitude Consultancy, the market is projected to grow from USD 14.5 billion in 2023 to USD 24.9 billion by 2030, at a strong CAGR of 8.6%.
The market includes diagnostics, CGM devices, insulin delivery systems, emergency care drugs, hospital-based monitoring…
Amyloidosis Clinical Market to Reach USD 8.3 Billion by 2030
The Global Amyloidosis Clinical Market is entering a significant growth phase driven by rapid adoption of targeted therapies, increased diagnostic capabilities, and expanding clinical research focused on subtypes like AL, ATTR, AA, and hereditary amyloidosis. According to Exactitude Consultancy, the market is projected to grow from USD 4.8 billion in 2023 to USD 8.3 billion by 2030, reflecting a CAGR of 7.9%.
Amyloidosis is a complex and often underdiagnosed condition involving…
Gaucher Disease Clinical Market to Reach USD 2.9 Billion by 2030
The Global Gaucher Disease Clinical Market is expanding steadily as advancements in enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy significantly improve outcomes for patients with this inherited lysosomal storage disorder. According to Exactitude Consultancy, the market is expected to grow from USD 1.8 billion in 2023 to USD 2.9 billion by 2030, achieving a CAGR of 6.5%.
The market encompasses diagnostics, drug therapies, patient monitoring, newborn screening…
More Releases for VVC
Vulvovaginal Candidiasis (VVC) Market to Reach $1.82 Billion by 2034, Growing at …
Introduction
Vulvovaginal Candidiasis (VVC), commonly known as yeast infection, is one of the most prevalent fungal infections affecting women globally. Caused predominantly by Candida albicans, VVC can lead to itching, inflammation, and discharge, significantly affecting quality of life. With nearly 75% of women experiencing at least one episode of VVC in their lifetime, the global healthcare landscape is increasingly emphasizing early diagnosis, effective therapeutics, and preventive strategies.
According to Exactitude Consultancy, the…
VVC Clothing Redefines Premium Streetwear with Motivational Designs That Celebra …
Fashion Brand Combines Remarkable Style with Inspirational Messaging to Empower "1 of 1" Customer Experience
VVC Clothing, is a premium streetwear and activewear brand, is revolutionizing the fashion industry by creating designs specifically intended to instil motivation and ambition into every outfit. The brand's unique approach reinforces customers' individual identities while delivering remarkable style that serves as daily inspiration for fashion-conscious men and women.
VVC Clothing has built its reputation on the…
Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Mar …
The Candidiasis Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Candidiasis Therapeutics Market Size and Projected Growth Rate?
Recent years have seen consistent growth in the size of the market for candidiasis therapeutics. This is predicted to further expand from $3.19 billion…
Candidiasis Therapeutics Market Size, Key Players, Demand And Outlook By 2033
The new report published by The Business Research Company, titled ""Candidiasis Therapeutics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in…
Acute Vulvovaginal Candidiasis Market Beyond Douching: New Treatment Options Dri …
Acute Vulvovaginal Candidiasis Market worth $ 485.54 Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, , Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast…
Acute Vulvovaginal Candidiasis Market Size, Share, Growth and Trends Study Repor …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acute Vulvovaginal Candidiasis Market- by Drug Type (Clotrimazole, Nystatin, Fluconazole, , Terbinafine, Terconazole and Other Drug Types), Route of Administration (Oral, Intravenous and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get Free Sample Copy of Report :https://www.insightaceanalytic.com/request-sample/1232
According to the latest research by InsightAce…
